ClinicalTrials.gg
CompletedNCT01320761Updated Mar 22, 2011

A Study to Assess Injection Comfort of Two Formulations of ATX-101

A Phase 1 interventional study of ATX-101-BA-free and ATX-101-BA in Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-22.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To assess the safety and injection comfort of ATX-101-BA versus ATX-101-BA-free immediately following injection and at regular intervals up to 24-hours post-injection following subcutaneous administration into the submental area.

02

Conditions studied

  • Healthy

Keywords

  • Formulation Comparison
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of submental fat graded by the investigator as 2, 3, or 4 using the CR-SMFRS (Appendix B).
  2. Sufficient and symmetrical submental fat such that the protocol-specified number of injections can be safely administered on both the right and left side.
  3. No difference in perception or sensitivity (pain or otherwise) between left and right sides of the submental area.
  4. Abstinence from alcohol for at least 6 hours prior to both the Baseline and 24-hour visits.
  5. Males or nonpregnant, nonlactating females who are aged 18 to 65 years, inclusive, on Baseline date.
  6. Females of must have a negative urine human chorionic gonadotropin (hCG) test result from a sample obtained during the screening period. Females of childbearing potential must agree to practice adequate , in the judgment of the investigator, during the course of the trial (including post-screening).
  7. The subject is expected to comply with and understand the visit schedule and all of the protocol-specified tests and procedures.
  8. The subject is medically able to undergo the administration of study material as determined by clinical and laboratory evaluations obtained within 14 days before dosing with study material for which the investigator identifies no abnormality.
  9. Signed obtained before any study-specific procedure is conducted.

Exclusion criteria

Exclusion Criteria:

  1. History of any intervention (e.g., liposuction) or trauma associated with the chin or neck areas, which in the judgment of the investigator, may affect subject safety or other evaluations of treatment.
  2. Evidence of any cause of enlargement in the submental area (e.g., thyroid enlargement, cervical adenopathy) other than localized submental fat.
  3. Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, thyroid dysfunction), that would interfere with the assessment of safety in this trial or would compromise the ability of the subject to undergo study procedures or to give .
  4. Any cognitive impairment that, in the Investigator's opinion, would preclude study participation or compliance with protocol-specified procedures.
  5. Treatment with analgesics or other agents that could affect the pain response, including but not limited to acetaminophen or ibuprofen taken within 1 day prior to Baseline; additionally, narcotic analgesics, tranquilizers, hypnotics, sedatives, or opiates within 7 days prior to Baseline.
  6. Treatment of the chin or SMF with injectable within 90 days prior to Baseline.
  7. Participation in a pain study within 6 months prior to Baseline.
  8. History of chronic pain and/or a history of chronic analgesic or tranquilizer use within 90 days prior to Baseline.
  9. Any anticipated need for agents with anticoagulative effects (e.g., aspirin, ibuprofen, warfarin, heparin) during the course of the trial.
  10. Treatment with oral anticoagulants (e.g., aspirin, warfarin) within 10 days prior to Baseline.
  11. Treatment with topical agents to the submental or neck area, including but not limited to creams or ointments used to treat dermatologic conditions (e.g., steroids, capsaicin, retinoids, fluorouracil) within 7 days prior to Baseline.
  12. Treatment with radio frequency, laser procedures, chemical peel, or dermal fillers in the neck or chin area within 12 months before dosing or botulinum toxin injections within 6 months prior to Baseline.
  13. Previous enrollment into this trial or treatment with ATX-101 or agents containing deoxycholate.
  14. Treatment with an agent within 28 days prior to Baseline.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1A

    Left side injected first: Left submental - ATX-101-BA Right submental - ATX-101-BA-free

    Drug: ATX-101-BA-free · Drug: ATX-101-BA

  • Experimental
    Group 1B

    Right side injected first: Left submental - ATX-101-BA Right submental - ATX-101-BA-free

    Drug: ATX-101-BA-free · Drug: ATX-101-BA

  • Experimental
    Group 2A

    Left side injected first: Left submental - ATX-101-BA-free Right submental - ATX-101-BA

    Drug: ATX-101-BA-free · Drug: ATX-101-BA

  • Experimental
    Group 2B

    Right side injected first: Left submental - ATX-101-BA-free Right submental - ATX-101-BA

    Drug: ATX-101-BA-free · Drug: ATX-101-BA

Interventions

06

What researchers measure

Primary outcomes

  1. Comfort measure

    The primary measure of comfort is the pain comparison scale between ATX-101-BA and ATX-101-BA-free at the time of injection using the pain comparison scale and the VAS pain rating scale.

    Time frame: up to 24 hours after treatment

07

Study locations

2 sites
  • Joel Schlessinger, M.D.
    Omaha, Nebraska 68144, United States
  • Jeffrey M. Adelglass, M.D.
    Plano, Texas 75093, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01320761
First posted
Mar 22, 2011
Last update
Mar 22, 2011

Study contacts

Patricia Walker, M.D.
study director · Kythera Biopharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion